Who cares, cur will be Funding Stem for a Long Long time...thank you.
One of the best moves by StemCells in 2013 was not discussed in McGlynn's letter to shareholders, but I believe it is worth mentioning. In October, StemCells acquired a patent portfolio that will help its future. The deal gives StemCells ownership of several patents that it already had exclusive worldwide licenses to, but relieves the company from paying any milestones or royalties in the future:
"The portfolio broadly claims the manufacture and proliferation of purified populations of human neural stem cell and their use as therapeutics and as tools for drug discovery."
To pay for the patents, StemCells issued 139,548 shares of stock, which was valued at $192,576 at the day of the announcement. One patent, which is valid through 2024, claims;
"use of human neural stem cells to remydinate endogenous host cells, such as to treat spinal cord injury."
Although the patents are broad, StemCells has the potential to keep its future dominance in the stem cell market and possibly see royalties from competitors along the way. After acquiring the patents, StemCells sued rival Neuralstem Inc. (CUR) for infringement on six of the patents. Neuralstem fought to have four of the six removed by the USPTO, but was denied. The denial by the USPTO likely means StemCells has a strong case and could see damages or potential royalties on any approved Neuralstem treatments. While this isn't the main reason to invest in StemCells, it certainly is worth watching in the future.